@article{ATM30596,
author = {Weiling Huang and Ying Song and Lixin Wang},
title = {Wenshen decoction suppresses inflammation in IL-33-induced asthma murine model via inhibiting ILC2 activation},
journal = {Annals of Translational Medicine},
volume = {7},
number = {20},
year = {2019},
keywords = {},
abstract = {Background: Wenshen decoction, consisting of Epimedium brevicornu Maxim, Morinda officinalis How and Cnidium monnieri (L.) Cusson, has favorable efficacy in the treatment of asthma in China.
Methods: The present study investigated the potential immunomodulatory mechanism underlying the therapeutic effects of Wenshen decoction on mouse asthma.
Results: Oral Wenshen decoction could ameliorate the production of IL-4, IL-5, IL-13 in the bronchoalveolar lavage fluid (BALF), reduce serum IgE, and improve the airway hyperresponsiveness (AHR) and airway inflammation in the BALB/c mice after intranasal treatment with recombinant IL-33. Moreover, Wenshen decoction reduced ILC2 and RORα mRNA expression, decreased the mRNA expression of ICOS and ST2 in the lung, but significantly increased the production of IFN-γ.
Conclusions: Our study indicates that Wenshen decoction may inhibit the activation of ILC2 through the IL-33/ST2/ICOS pathway to further suppress airway inflammation and AHR in the asthmatic mice, and the increased IFN-γ might be related to the effects of Wenshen decoction on ILC2.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/30596}
}